TSQ (CAS 109628-27-5)

TSQ, represents a novel small molecule inhibitor targeting protein kinase C-α (PKC-α), an enzyme of significance. Due to its remarkable ability to inhibit PKC-α and its notable stability, TSQ has found extensive usage in diverse scientific research applications. Among its varied applications, one of the most prominent roles of TSQ lies in the study of cancer cell growth. It has demonstrated its efficacy in impeding the growth of specific cancer cell types, making it a valuable asset for researchers exploring this disease. Furthermore, TSQ has contributed to the examination of neuronal cell death, apoptosis, and certain immune responses. The mechanism underlying TSQ′s action is elegantly straightforward. By binding to the active site of the enzyme PKC-α, TSQ effectively obstructs the enzyme′s normal catalytic activity. Consequently, this inhibition of PKC-α elicits a range of cellular responses, contingent upon the cell type and the concentration of TSQ employed. This fundamental interaction paves the way for a myriad of investigative avenues within the scientific community.